Drugs / abobotulinumtoxinA
last change May 2026 re-read 3 minutes ago

abobotulinumtoxinA

also known as AboBoNT-A

Protein / enzyme biologic targets SNAP25 via inhibition

Investigated by
Ipsen

Trials 1

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT04936542 Jun 2021 → Aug 2025 — Ipsen Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as abobotulinumtoxinA “Lack of head-to-head comparative safety and efficacy data for abobotulinumtoxinA (aboBoNT-A) and onabotulinumtoxinA (onaBoNT-A) represented an important gap for informed...” PMID 42159955 ↗ May 2026
Known as AboBoNT-A ClinicalTrials.gov intervention name — accepted as the source's own label NCT04936542 ↗
Action Inhibit “Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor” CHEMBL2108570 ↗
Modality Protein / enzyme biologic “Biological: AboBoNT-A” NCT04936542 ↗
Route Intramuscular “To maintain blinding, a fixed volume (3.6 ml) will be injected into the target upper limb muscles (four wrist and finger flexors and biceps brachii).” PMID 34562231 ↗ Sep 2021
Target SNAP25 “Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor” CHEMBL2108570 ↗